OSE Immunotherapeutics - Publication puts Tedopi back in the spotlight
OSE has announced that the results from its Phase III trial (ATALANTE-1) for Tedopi have been published in Annals of Oncology. While the study...
363 Views
OSE Immunotherapeutics - Grant to weave RNA into R&D platform
OSE Immunotherapeutics (OSE) has announced that it has received grant innovation funding of €200,000 from the French government and Region Pays de...
301 Views
OSE Immunotherapeutics - Lusvertikimab progressing on multiple fronts
OSE has announced that Lusvertikimab (or OSE-127), the company’s most advanced asset in the immuno-inflammation space, has received a positive...
241 Views
OSE Immunotherapeutics - US patent to bolster Tedopi’s product portfolio
OSE Immunotherapeutics has announced that Tedopi, the company’s lead cancer vaccine candidate, has been granted a new patent by the United States...
357 Views
OSE Immunotherapeutics - New diagnostic test to support Tedopi trial
OSE Immunotherapeutics (OSE) has received €1.5m in non-dilutive funding from Bpifrance (a French public sector investment bank) to develop a...
107 Views